



BTC HEALTH TO ACQUIRE HOSPITAL INFUSION BUSINESS

- **BTC health takes decisive step to become a leading supplier of innovative medical products.**
- **Acquisition of exclusive rights to ambIT® range of infusion pumps for Australia and New Zealand**
- **Forecast annual revenues of \$7 million p.a. and growing at 14% p.a.**
- **Purchase price of \$6.3 million which includes \$1.75 million of working capital**
- **Establishes a platform for anticipated strong growth and new product introductions commencing 2H2019.**

BTC health (ASX: BTC) is pleased to announce today that its wholly owned subsidiary BTC Speciality Health Pty Ltd (BTC Speciality Health) has entered into an agreement with Admedus Limited (ASX: AHZ) to acquire part of its Hospital Infusion Business.

The acquisition includes the novation of an 8-year exclusive distribution agreement with Summit Medical Products for the ambIT® range of infusion pumps in Australia and New Zealand, purchase of all saleable inventory and the transfer of certain key employees including Glenn Gilchrist the current Infusion Business Unit Head. BTC health will not acquire the right to the Arcomed and Leventon range of infusion pumps which remain with Admedus.

The innovative ambIT® infusion pumps provide patients, doctors and hospitals with a portable, flexible and cost-effective alternative to traditional stationary pumps. They are designed to allow patients the ability to receive drug infusions including pain management, chemotherapy and antibiotic infusions in the hospital or at home. They are powered, lightweight portable devices offering the treatment flexibility of stationary pumps at a significantly lower cost.

Annual sales of the ambIT® infusion pumps for FY20 are forecast to be approximately \$7 million with continuing growth of at least 14% per annum. This acquisition gives the BTC health group a strong platform to drive organic growth in the private and public hospitals within Australia and New Zealand, as well as providing the capabilities and infrastructure for new product introductions starting in 2H2019.

The purchase price for the business is \$6.3 million, which includes \$1.75 million of working capital upon completion. The sale is expected to complete on 31 May 2019 and is subject to certain conditions including BTC health completing a capital raise to finance the transaction. BTC health intends to fund this acquisition through a two-tranche private placement and a share purchase plan.

BTC health Executive Chairman Richard Treagus commented; "We are excited to be acquiring the rights to these infusion products from Admedus. It is a transformative acquisition for BTC health which brings established revenues, a quality range of innovative hospital products and an experienced national sales and specialist education team. This gives the BTC health group a platform for growth which can be

leveraged to deliver strong organic growth and provide the capability and capacity for the introduction of new products from the BTC health pipeline.”

For more information please contact:

Dr. Richard Treagus, Executive Chairman
rtreagus@btchealth.com
+61 417 520 509

Forward-looking Statements

This ASX-announcement contains forward-looking statements that are subject to risks and uncertainties. Such statements involve known and unknown risks and important factors that may cause the actual results, performance or achievements of BTC health to be materially different from the statements in this announcement.

About BTC health

BTC health is a listed entity on the ASX and is a Pooled Development Fund, registered under the Pooled Development Funds Act 1992. The company’s strategy is to make active investments in businesses that acquire, develop and commercialize product opportunities in the healthcare space and which will benefit from greater access to development capital. The company has the long-term objective of building a group of complementary high-growth businesses which operate together and generate better patient health outcomes and value for its shareholders.

Under the Pooled Development Funds Act 1992, shareholders are entitled to concessionary tax treatment in Australia for income and capital gains derived in connection with their shareholding. Gains realised on the disposal of shares will not be included in an investor’s assessable income in Australia. An investor will not be entitled to any deduction or capital loss on the sale of shares. Unfranked dividends received by an Australian resident will be exempt from tax. Franked dividends will also be exempt from tax unless the shareholder elects to be taxed. An Australian corporate tax entity may credit its franking account (with franking credits attaching to a franked dividend), regardless of whether it has elected to treat the dividend as exempt or assessable income. Dividends paid to non-residents will not be subject to withholding tax. A shareholder or prospective shareholder should obtain their own tax advice rather than relying on this summary

About Summit Medical Products

Summit Medical Products, Inc. is a privately-held, employee-owned company located in Salt Lake City, Utah, USA. Summit has broad experience in the design, development and distribution of medical products. Summit’s primary focus is the ambIT® infusion pumps which are sold worldwide and the company invests heavily in new product development.